Second Window Indocyanine Green for All Nervous System Tumors

• Status: Not yet recruiting
• Trial end date: 2025-02-15
• Target enrollment: 0
• Participant gender: All

Summary

The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abramson Cancer Center of the University of Pennsylvania

Criteria

Inclusion Criteria:

1. Adult patients 18 years of age and older

2. Patients presenting with a nervous system tumor presumed to be resectable and at risk for local recurrence on pre-operative assessment

3. Good operative candidates, as determined by the treating physician and multidisciplinary team

4. Subjects capable of giving informed consent

Exclusion Criteria:

1. Pregnant women, as determined by urinary or serum beta hCG within 48 hours of surgery

2. Subjects with a history of iodide allergies

3. Vulnerable patient populations

4. Patients unable to participate in the consent process

5. Patients with history of uncontrolled HTN (requiring ER admission or ≥ 3 BP medications)